BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Dimethylphenylpiperazinium Iodide

A selective nicotinic cholinergic agonist used as a research tool. DMPP activates nicotinic receptors in autonomic ganglia but has little effect at the neuromuscular junction.

33+ PubMed studies analyzed · Evidence Score: 32.4

Research Domains

Dimethylphenylpiperazinium Iodide has been studied across 17 research domains including 🧠 Focus & Attention, 🫘 Kidney, 🦴 Bone & Joint, ❤️ Cardiovascular, 🔬 Oncology. The primary research focus is 🧠 Focus & Attention with 36% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Dimethylphenylpiperazinium Iodide, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Mecamylamine
11 shared targets
Lobeline
11 shared targets
Arecoline
11 shared targets
Nicotine
11 shared targets
mg624
10 shared targets
Dihydro-beta-Erythroidine
4 shared targets
Diiodotyrosine
5 shared targets
Anabasine
3 shared targets
Ibogaine
4 shared targets
Cefotetan
4 shared targets
Loading evidence profile...

This evidence profile for Dimethylphenylpiperazinium Iodide is generated deterministically from 33 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.